Diversified healthcare bellwether Johnson & Johnson (NYSE:JNJ) reported decent third quarter sales trends on October 18, though profits fell. Despite continued tepid near-term results, J&J stands out for its product and sales diversification. And though upside potential remains questionable, the stock has protected investors on the downside. Year-to-date, it is up 5% while the overall market is down about 5%.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Third Quarter Recap
Sales advanced 6.8% to $16 billion, though operational growth was quite modest at 2.6%. Positive currency fluctuations accounted for 4.2% of the total quarterly growth. International sales improved a healthy 8.3% organically, while positive foreign exchange movements boosted reported overseas growth to 16.4% and 57% of total sales. Domestic trends were more challenging, as sales fell 3.7% to account for 43% of total sales.

By product area, reported medical device sales rose 1.7% and represented close to 40% of the total top line. Pharmaceutical sales represented the next-largest category at more than 37% of total sales. This category saw sales jump 8.9%, as international sales rose 27.5% and offset a 6.1% domestic decline, due primarily to generic competition of bacterial-treatment drug Levaquin. Consumer sales made up the remaining 23% of sales and grew a healthy 4.9%, despite a number of remaining product recalls and "ongoing efforts to enhance quality and manufacturing systems".

A double-digit increase in selling costs and operating selling, marketing and administrative expenses sent operating income down 2.6% to $4.1 billion. Income tax expense also jumped in the double digits and sent net income down 6.3% to $3.2 billion, or $1.15 diluted earnings per share (diluted EPS). However, this still resulted in an impressive net profit margin of 20%. (To learn more about investment quality, check out: Find Investment Quality In The Income Statement.)

Outlook
J&J expects to report full-year earnings between $4.95 and $5 diluted EPS, excluding the impact of special items. Analysts currently project full-year sales growth of 6% and total sales of more than $65 billion.

Bottom Line
J&J trades at a reasonable forward P/E of 13 and sports an above-average dividend yield of 3.5%. However, growth in recent years has been an issue. Over the past three years, sales have barely budged, though earnings are up close to 10% annually on average. The five-year figures show stronger annual sales growth of 4%, but weaker profit growth of below 7%.

Compared to pure-play pharmaceutical rivals including Pfizer (NYSE:PFE) and Merck (NYSE:MRK), J&J has a clearer growth profile, though this is due in good part to its non-pharma divisions. The consumer unit should eventually see a sales rebound from a surprising number of product recalls and manufacturing deficiencies. The medical device unit also continues to benefit from strong demand and acquisitions, though pure-play rival Medtronic (NYSE:MDT) currently looks like a better bet at less than 10 times forward earnings. But J&J still represents one of the best ways to play a broad array of healthcare product categories across the globe. Abbott Laboratories (NYSE:ABT) is an equally compelling play and trades at a forward P/E of just over 11.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Products and Investments

    Cash vs. Stocks: How to Decide Which is Best

    Is it better to keep your money in cash or is a down market a good time to buy stocks at a lower cost?
  2. Investing News

    Who Does Cheap Oil Benefit? See This Stock (DG)

    Cheap oil won't benefit most companies, but this retailer might buck that trend.
  3. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  4. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  5. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  6. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  7. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  8. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  9. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  10. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center